Research ExplorerPublicationsImpact of Molecular Genetics on Outcome in Myelofibrosis Pat...

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

Standard

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. / Kröger, Nicolaus; Panagiota, Victoria; Badbaran, Anita; Zabelina, Tatiana; Triviai, Ioanna; Araujo Cruz, Michelle Maria; Shahswar, Rabia; Ayuketang, Francis Ayuk; Gehlhaar, Marten; Wolschke, Christine; Bollin, Robin; Walter, Carolin; Dugas, Martin; Wiehlmann, Lutz; Lehmann, Ulrich; Koenecke, Christian; Chaturvedi, Anuhar; Alchalby, Haefaa; Stadler, Michael; Eder, Matthias; Christopeit, Maximilian; Göhring, Gudrun; Koenigsmann, Michael; Schlegelberger, Brigitte; Kreipe, Hans-Heinrich; Ganser, Arnold; Stocking, Carol ; Fehse, Boris; Thol, Felicitas; Heuser, Michael.

In: BIOL BLOOD MARROW TR, Vol. 23, No. 7, 07.2017, p. 1095-1101.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Panagiota, V, Badbaran, A, Zabelina, T, Triviai, I, Araujo Cruz, MM, Shahswar, R, Ayuketang, FA, Gehlhaar, M, Wolschke, C, Bollin, R, Walter, C, Dugas, M, Wiehlmann, L, Lehmann, U, Koenecke, C, Chaturvedi, A, Alchalby, H, Stadler, M, Eder, M, Christopeit, M, Göhring, G, Koenigsmann, M, Schlegelberger, B, Kreipe, H-H, Ganser, A, Stocking, C, Fehse, B, Thol, F & Heuser, M 2017, 'Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation', BIOL BLOOD MARROW TR, vol. 23, no. 7, pp. 1095-1101. https://doi.org/10.1016/j.bbmt.2017.03.034

APA

Kröger, N., Panagiota, V., Badbaran, A., Zabelina, T., Triviai, I., Araujo Cruz, M. M., Shahswar, R., Ayuketang, F. A., Gehlhaar, M., Wolschke, C., Bollin, R., Walter, C., Dugas, M., Wiehlmann, L., Lehmann, U., Koenecke, C., Chaturvedi, A., Alchalby, H., Stadler, M., ... Heuser, M. (2017). Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. BIOL BLOOD MARROW TR, 23(7), 1095-1101. https://doi.org/10.1016/j.bbmt.2017.03.034

Vancouver

Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM et al. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. BIOL BLOOD MARROW TR. 2017 Jul;23(7):1095-1101. https://doi.org/10.1016/j.bbmt.2017.03.034

Bibtex

@article{c9f83d68856e4b6fa2b4b12885f5c587,
title = "Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation",
abstract = "Molecular genetics may influence outcome for patients with myelofibrosis. To determine the impact of molecular genetics on outcome after allogeneic stem cell transplantation, we screened 169 patients with primary myelofibrosis (n = 110), post-ET/PV myelofibrosis (n = 46), and myelofibrosis in transformation (n = 13) for mutations in 16 frequently mutated genes. The most frequent mutation was JAK2V617F (n = 101) followed by ASXL1 (n = 49), calreticulin (n = 34), SRSF2 (n = 16), TET2 (n = 10), U2AF1 (n = 11), EZH2 (n = 7), MPL (n = 6), IDH2 (n = 5), IDH1 (n = 4), and CBL (n = 1). The cumulative incidence of non-relapse mortality (NRM) at 1 year was 21% and of relapse at 5 years 25%. The 5-year progression-free and overall survival (PFS and OS) was 52% and 56%, respectively. In a multivariate analysis CALR mutation was an independent factor for lower NRM (hazard ratio (HR) 0.415, p = 0.05), improved PFS (HR 0.393, p = 0.01), and OS (HR 0.448, p = 0.03). ASXL1 and IDH2 mutations were independent risk factors for lower PFS (HR 1.53, p = 0.008 and HR 5.451, p = 0.002, respectively), while no impact was observed for {"}triple negative{"} patients. Molecular genetics, especially CALR, IDH2, and ASXL1 mutations, may thus be useful to predict outcome independently from known clinical risk factors after allogeneic stem cell transplantation for myelofibrosis.",
keywords = "Journal Article",
author = "Nicolaus Kr{\"o}ger and Victoria Panagiota and Anita Badbaran and Tatiana Zabelina and Ioanna Triviai and {Araujo Cruz}, {Michelle Maria} and Rabia Shahswar and Ayuketang, {Francis Ayuk} and Marten Gehlhaar and Christine Wolschke and Robin Bollin and Carolin Walter and Martin Dugas and Lutz Wiehlmann and Ulrich Lehmann and Christian Koenecke and Anuhar Chaturvedi and Haefaa Alchalby and Michael Stadler and Matthias Eder and Maximilian Christopeit and Gudrun G{\"o}hring and Michael Koenigsmann and Brigitte Schlegelberger and Hans-Heinrich Kreipe and Arnold Ganser and Carol Stocking and Boris Fehse and Felicitas Thol and Michael Heuser",
note = "Copyright {\textcopyright} 2017. Published by Elsevier Inc.",
year = "2017",
month = jul,
doi = "10.1016/j.bbmt.2017.03.034",
language = "English",
volume = "23",
pages = "1095--1101",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

AU - Kröger, Nicolaus

AU - Panagiota, Victoria

AU - Badbaran, Anita

AU - Zabelina, Tatiana

AU - Triviai, Ioanna

AU - Araujo Cruz, Michelle Maria

AU - Shahswar, Rabia

AU - Ayuketang, Francis Ayuk

AU - Gehlhaar, Marten

AU - Wolschke, Christine

AU - Bollin, Robin

AU - Walter, Carolin

AU - Dugas, Martin

AU - Wiehlmann, Lutz

AU - Lehmann, Ulrich

AU - Koenecke, Christian

AU - Chaturvedi, Anuhar

AU - Alchalby, Haefaa

AU - Stadler, Michael

AU - Eder, Matthias

AU - Christopeit, Maximilian

AU - Göhring, Gudrun

AU - Koenigsmann, Michael

AU - Schlegelberger, Brigitte

AU - Kreipe, Hans-Heinrich

AU - Ganser, Arnold

AU - Stocking, Carol

AU - Fehse, Boris

AU - Thol, Felicitas

AU - Heuser, Michael

N1 - Copyright © 2017. Published by Elsevier Inc.

PY - 2017/7

Y1 - 2017/7

N2 - Molecular genetics may influence outcome for patients with myelofibrosis. To determine the impact of molecular genetics on outcome after allogeneic stem cell transplantation, we screened 169 patients with primary myelofibrosis (n = 110), post-ET/PV myelofibrosis (n = 46), and myelofibrosis in transformation (n = 13) for mutations in 16 frequently mutated genes. The most frequent mutation was JAK2V617F (n = 101) followed by ASXL1 (n = 49), calreticulin (n = 34), SRSF2 (n = 16), TET2 (n = 10), U2AF1 (n = 11), EZH2 (n = 7), MPL (n = 6), IDH2 (n = 5), IDH1 (n = 4), and CBL (n = 1). The cumulative incidence of non-relapse mortality (NRM) at 1 year was 21% and of relapse at 5 years 25%. The 5-year progression-free and overall survival (PFS and OS) was 52% and 56%, respectively. In a multivariate analysis CALR mutation was an independent factor for lower NRM (hazard ratio (HR) 0.415, p = 0.05), improved PFS (HR 0.393, p = 0.01), and OS (HR 0.448, p = 0.03). ASXL1 and IDH2 mutations were independent risk factors for lower PFS (HR 1.53, p = 0.008 and HR 5.451, p = 0.002, respectively), while no impact was observed for "triple negative" patients. Molecular genetics, especially CALR, IDH2, and ASXL1 mutations, may thus be useful to predict outcome independently from known clinical risk factors after allogeneic stem cell transplantation for myelofibrosis.

AB - Molecular genetics may influence outcome for patients with myelofibrosis. To determine the impact of molecular genetics on outcome after allogeneic stem cell transplantation, we screened 169 patients with primary myelofibrosis (n = 110), post-ET/PV myelofibrosis (n = 46), and myelofibrosis in transformation (n = 13) for mutations in 16 frequently mutated genes. The most frequent mutation was JAK2V617F (n = 101) followed by ASXL1 (n = 49), calreticulin (n = 34), SRSF2 (n = 16), TET2 (n = 10), U2AF1 (n = 11), EZH2 (n = 7), MPL (n = 6), IDH2 (n = 5), IDH1 (n = 4), and CBL (n = 1). The cumulative incidence of non-relapse mortality (NRM) at 1 year was 21% and of relapse at 5 years 25%. The 5-year progression-free and overall survival (PFS and OS) was 52% and 56%, respectively. In a multivariate analysis CALR mutation was an independent factor for lower NRM (hazard ratio (HR) 0.415, p = 0.05), improved PFS (HR 0.393, p = 0.01), and OS (HR 0.448, p = 0.03). ASXL1 and IDH2 mutations were independent risk factors for lower PFS (HR 1.53, p = 0.008 and HR 5.451, p = 0.002, respectively), while no impact was observed for "triple negative" patients. Molecular genetics, especially CALR, IDH2, and ASXL1 mutations, may thus be useful to predict outcome independently from known clinical risk factors after allogeneic stem cell transplantation for myelofibrosis.

KW - Journal Article

U2 - 10.1016/j.bbmt.2017.03.034

DO - 10.1016/j.bbmt.2017.03.034

M3 - SCORING: Journal article

C2 - 28389256

VL - 23

SP - 1095

EP - 1101

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 7

ER -